Crysvita

Crysvita

$4,071.01 – $10,926.90

Crysvita (burosumab) is indicated for the treatment of X-linked hypophosphatemia (XLH) and Tumor-induced osteomalacia (TIO).

SKU: N/A Categories: ,

What is Crysvita (burosumab) for?

Crysvita (burosumab) is indicated for the treatment of:

  • X-linked hypophosphatemia (XLH).
  • Tumor-induced osteomalacia (TIO)

Approved presentations:

  • 10 mg/mL in single dose vial
  • 20 mg/mL in single dose vial
  • 30 mg/mL in single dose vial

Where has Crysvita (burosumab) been approved?

Crysvita (burosumab) has been approved for the treatment of:

  • X-linked hypophosphataemia (XLH) in adult and pediatric patients 6 months of age and older, by
    • The Food and Drug Administration (FDA) on April 17, 2018.
    • The European Medicines Agency (EMA) on February 19, 2018.
    • Health Canada on December 06, 2018.
  • Tumor-induced osteomalacia (TIO), by
    • The FDA on June 18, 2020.
    • Health Canada on September 07, 2021
Single-dose vial

1 single-dose vial of 10 mg/mL, 1 single-dose vial of 20 mg/mL, 1 single-dose vial of 30 mg/mL

Related products